Vanderbilt biostatisticians have developed an immunotherapy response model that outperforms existing predictive models.
Biostatisticians at VUMC have played a pivotal role in the redesign of clinical trials that rigorously and rapidly determine the effectiveness of life-saving treatments for acutely ill patients.
Vanderbilt’s Jennifer Pietenpol, PhD, and Yu Shyr, PhD, have been inducted as fellows of the American Association for Cancer Research Academy.
A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors.
Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in JAMA Oncology.